Weight Reduction Center
Weight Reduction Center · 6029 Cermak Road · Cicero, IL 60804
4.8· 45 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- GLP-1 medications named on site
- Medically supervised weight loss
About this practice
Weight Reduction Center is a physician-led weight-loss program in Cicero, Illinois, established by Octavio M. Lopez, MD, FACP, who per its website is board certified in bariatric medicine and internal medicine. The site says the program has helped patients for over ten years, uses only FDA-approved medications and methods it calls proven, and offers one-on-one treatment with diet programs customized to each patient's lifestyle, work schedule and eating habits. Telehealth is available, and the practice lists semaglutide. On Google it holds a 4.8-star rating across 45 reviews dating back to 2015, with reviewers mentioning results and a caring staff.
Services & access
| Advertises semaglutide today | Yes |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Yes |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2025-11-13. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★4.8 across 45 Google reviews. Of the 45 reviews we analyzed, 44 (98%) are positive (4–5★) and 1 (2%) are negative (1–2★).
What patients like
- Weight-loss results3 reviews
Common complaints
Very few complaints — only 1 negative review, with no recurring theme.
Most recent Google reviews
Claudia O.★★★★★2025-11-13El mejor doctor excelente método para bajar de peso todo combinado con alimentación 🥦🍇🥑🍑🍋🍉🍗🥩saludable y con buen ejercicio 🏋🏽♀️como cualquier método 10 ⭐️⭐️⭐️⭐️⭐️⭐️⭐️⭐️⭐️⭐️
Fabiola O.★★★★★2025-11-12I have been taking the shots for 2 months and it has been great! I highly recommend Dr. Lopez. He is such a wonderful and friendly person.
Martin C.★★★★★2023-09-23Great experience during the visit and throughout my journey of losing and maintaining my weight goals. Dr Lopez is very understanding, he listens to your weight struggles and provides real solutions that work and provide a guide for changing habits to incorporate in your life style for a permanent solution. I highly recommend Dr Lopez weight management tools for people of all ages!
Mayra J.★★★★★2023-03-05Dr. Lopez is amazing! Very informative and supporting throughout the journey!
Clotilde C.★★★★★2023-01-14Place is great he takes time and helps and motivates you to lose weight.
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs